The glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and now next-generation multi-agonists that include GLP-1 activity, are producing average weight reductions far larger than previously expected from drugs, reshaping clinical practice and how clinicians and patients think about obesity treatment
Eur J Med Chem
In phase 2b trials, a 54-week regimen of daily subcutaneous cotadutide injections (100, 200, or 300 g) significantly lowered HbA1c levels compared to placebo
While GLP-1s can help users lose 15 to 20% of their body weight, research shows that long-term success depends on daily habits, mindset, and lifestyle changes
After 8 weeks of treatment, the weight decreased by -1.4-3.3kg (122)
All medical content on this blog is created using reputable, evidence-based sources and is regularly reviewed for accuracy and relevance